Kineta
Ray is on the board of Kineta, a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies to address the major challenges with current cancer therapy. Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies.
Kineta has assembled an experienced management team, a seasoned research and development team, an immuno-oncology focused scientific advisory board, an enabling technology platform and a leading intellectual property position to advance its pipeline of potential novel immunotherapies for cancer patients.
Kineta opened a Phase 1 clinical study evaluating their lead drug candidate KVA12123 as a single agent and in combination with their partner Merck’s Keytruda (pembrolizumab). The drug is being tested in patients with advanced solid tumors. The novel target protein VISTA is expressed in cancer cells and allows tumors to evade the immune system.
